Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce that, further to its news release on October 29, 2025 it has closed a non-brokered private placement and issued 30 class A multiple voting shares ("Class A Multiple Voting Shares") of the Company at a price of $25 Per Class A Multiple Voting Shares for gross proceeds of $750 (the "Offering").

Newsfile Corp • Dec 11, 2025

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

TORONTO, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News' flagship investigative program W5 has aired Part 2 of a three-part series about Quantum Biopharma and the company's allegations of stock market manipulation.

GlobeNewsWire • Nov 27, 2025

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

TORONTO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News' flagship investigative program W5 will air, starting today, a three-part series about Quantum Biopharma and the company's allegations of stock market manipulation.

GlobeNewsWire • Nov 26, 2025

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Quarter Shows Company's Continued Strong Financial Position and Momentum with its MS Clinical Trials and unbuzzd™ Recreational Beverage and Alcohol Metabolizer Quarter Shows Company's Continued Strong Financial Position and Momentum with its MS Clinical Trials and unbuzzd™ Recreational Beverage and Alcohol Metabolizer

GlobeNewsWire • Nov 7, 2025

Quantum BioPharma Ltd. Provides Corporate Update

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K9A) (“Quantum” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that pursuant to the entry into its previously announced at the market offering agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) on February 16, 2024, announces today, the Company at its discretion may offer and sell, from time to time, through Wainwright as sales agent, Class B Subordinate Voting Shares in the capital of the Company (“Class B Shares”) having an aggregate offering price of up to US$21,225,000 (the “ATM Offering”). A cash commission of 3.0% on the aggregate gross proceeds raised under the ATM Offering will be paid to Wainwright in connection with its services.

GlobeNewsWire • Oct 31, 2025

Quantum BioPharma Ltd. Announces Corporate Updates

Toronto, Ontario--(Newsfile Corp. - October 29, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces, as approved by the shareholders of the Company at the annual general and special meeting of shareholders held on September 26, 2025, a non-brokered private placement of up to 30 class A multiple voting shares of the Company ("Class A Multiple Voting Shares") at a price of $25 per Class A Multiple Voting Shares, for aggregate gross proceeds of up to $750 (the "Offering").

Newsfile Corp • Oct 30, 2025

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced its licensee, Unbuzzd Wellness Inc. ("Unbuzzd"), the company behind unbuzzdTM — the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms — as part of its Reg D 506 (c) offering and up to $5 million raise, will host an Investor Webinar on Thursday, October 30, 2025 at 4:15 pm EST (1:15 pm PST). The shareholders of Quantum BioPharma will not be diluted by this offering.

GlobeNewsWire • Oct 23, 2025

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the expiration at 5pm EST of 53,147 warrants (originally 3,454,543 warrants issued pre-reverse stock split (65 to 1)). All warrants were issued to hedge funds and investment funds as part of a previous financing completed on October 20, 2020. This represents the very last tranche of warrants issued to hedge funds and investment funds.

GlobeNewsWire • Oct 20, 2025

Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group

TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today issued a formal response to the press releases published by The Schall Law Firm and DJS Law Group on October 9th and 10th , 2025, which announced an investigation into alleged securities law violations by the Company.

GlobeNewsWire • Oct 14, 2025

QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $QNTM--QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm.

Business Wire • Oct 9, 2025